Junshi Biosciences and Coherus BioSciences unveiled data from the Phase III HEPATORCH study, showing that its PD-1 inhibitor Loqtorzi (toripalimab)—when used with bevacizumab—significantly improved survival in patients with advanced hepatocellular carcinoma.
Tag Archive for: Coherus
For Sandoz, Monday’s deal with Coherus represents its first major contract since spinning out of Novartis in October 2023.